Paradoxical response in a patient with non-small cell lung cancer who received nivolumab followed by anti-Mycobacterium tuberculosis agents

Journal of Infection and Chemotherapy

Volumn 25, Issue 1, 2019, Pages 54-58

  Takata, So ^a   Koh, Genju ^b   Han, Yuki ^a   Yoshida, Hiroko ^a   Shiroyama, Takayuki ^a   Takada, Hiromune ^a   Masuhiro, Kentarou ^a   Nasu, Shingo ^a   Morita, Satomu ^a   Tanaka, Ayako ^a   Hashimoto, Syouji ^a   Uriu, Kiyoaki ^b   Suzuki, Hidekazu ^a   Tamura, Yoshitaka ^a   Okamoto, Norio ^a   Nagai, Takayuki ^a   Hirashima, Tomonori ^a  

^a OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

^b Yao Tokushukai General Hospital   (Japan)

Author keywords

Immune reconstitution inflammatory syndrome; Lung cancer; Mycobacterium tuberculosis; Paradoxical response; PD 1; Pseudoprogression

Indexed keywords

CARBOPLATIN; CARCINOEMBRYONIC ANTIGEN; ETHAMBUTOL; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; ISONIAZID; MOXIFLOXACIN; NIVOLUMAB; PACLITAXEL; PEMETREXED; PREDNISOLONE; PYRAZINAMIDE; RIFAMPICIN; SULTAMICILLIN; TUBERCULOSTATIC AGENT; ANTIINFECTIVE AGENT; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

AGED; ANEMIA; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL PNEUMONIA; CASE REPORT; CLINICAL ARTICLE; COUGHING; DRUG WITHDRAWAL; FEVER; HUMAN; HYPOALBUMINEMIA; IMMUNE RESPONSE; JAPANESE (PEOPLE); LUNG ADENOCARCINOMA; LUNG TUBERCULOSIS; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; MYCOBACTERIUM TUBERCULOSIS; SPUTUM CULTURE; TACHYCARDIA; TREATMENT RESPONSE; UPREGULATION; ADENOCARCINOMA; COMPLICATION; DRUG EFFECT; GENETICS; LUNG; LUNG TUMOR; MICROBIOLOGY; MULTIDRUG RESISTANCE; NON SMALL CELL LUNG CANCER; PATHOLOGY; SPUTUM;

ADENOCARCINOMA; AGED; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; LUNG; LUNG NEOPLASMS; MALE; MYCOBACTERIUM TUBERCULOSIS; NIVOLUMAB; SPUTUM; TUBERCULOSIS, PULMONARY;

EID: 85050345478     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1016/j.jiac.2018.06.016     Document Type: Article

References (14)

1. Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D.R., Steins, M., Ready, N.E., et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:17 (2015), 1627–1639.
2. Brahmer, J., Reckamp, K.L., Baas, P., Crino, L., Eberhardt, W.E., Poddubskaya, E., et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373:2 (2015), 123–135.
3. Reck, M., Rodriguez-Abreu, D., Robinson, A.G., Hui, R., Csoszi, T., Fulop, A., et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375:19 (2016), 1823–1833.
4. Fujita, K., Terashima, T., Mio, T., Anti-PD1 antibody treatment and the development of acute pulmonary tuberculosis. J Thorac Oncol 11:12 (2016), 2238–2240.
5. Lee, J.J., Chan, A., Tang, T., Tuberculosis reactivation in a patient receiving anti-programmed death-1 (PD-1) inhibitor for relapsed Hodgkin's lymphoma. Acta Oncol 55:4 (2016), 519–520.
6. Chu, Y.C., Fang, K.C., Chen, H.C., Yeh, Y.C., Tseng, C.E., Chou, T.Y., et al. Pericardial tamponade caused by a hypersensitivity response to tuberculosis reactivation after anti-PD-1 treatment in a patient with advanced pulmonary adenocarcinoma. J Thorac Oncol 12:8 (2017), e111–e114.
7. Picchi, H., Mateus, C., Chouaid, C., Besse, B., Marabelle, A., Michot, J.M., et al. Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment. Clin Microbiol Infect 24:3 (2018 Mar), 216–218.
8. Cheng, V.C., Ho, P.L., Lee, R.A., Chan, K.S., Chan, K.K., Woo, P.C., et al. Clinical spectrum of paradoxical deterioration during antituberculosis therapy in non-HIV-infected patients. Eur J Clin Microbiol Infect Dis 21:11 (2002), 803–809.
9. Church, L.W.P., Chopra, A., Judson, M.A., Paradoxical reactions and the immune reconstitution inflammatory syndrome. Microbiol Spectr, 5(2), 2017.
10. Cheng, S.L., Wang, H.C., Yang, P.C., Paradoxical response during anti-tuberculosis treatment in HIV-negative patients with pulmonary tuberculosis. Int J Tuberc Lung Dis 11:12 (2007), 1290–1295.
11. Bell, L.C., Breen, R., Miller, R.F., Noursadeghi, M., Lipman, M., Paradoxical reactions and immune reconstitution inflammatory syndrome in tuberculosis. Int J Infect Dis 32 (2015), 39–45.
12. Hassan, S.S., Akram, M., King, E.C., Dockrell, H.M., Cliff, J.M., PD-1, PD-L1 and PD-L2 gene expression on t-cells and natural killer cells declines in conjunction with a reduction in PD-1 protein during the intensive phase of tuberculosis treatment. PLoS One, 10(9), 2015 e0137646.
13. Kato, R., Hayashi, H., Tanizaki, J., Tanaka, K., Takeda, M., Nakagawa, K., Peritumoural ground-glass opacity associated with tumour pseudoprogression in a patient with non-small cell lung cancer treated with nivolumab. ESMO Open, 2(1), 2017 e000145.
14. Wykes, M.N., Lewin, S.R., Immune checkpoint blockade in infectious diseases. Nat Rev Immunol 18:2 (2018), 91–104.